Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis Pain (RF-PROSPECTIU)
A Prospective Comparative Study of Conventional Conservative Treatment Versus Genicular Radiofrequency Ablation in Non-Surgical Knee Osteoarthritis: A Randomized Controlled Trial of Thermal Radiofrequency of the Genicular Nerves Versus Intra-Articular Hyaluronic Acid
The goal of this clinical trial is to learn if thermal radiofrequency ablation of the genicular nerves (the nerves that carry pain signals from the knee) works better than a single injection of hyaluronic acid into the knee to relieve pain in adults with knee osteoarthritis who have not improved with conservative treatment. The study also includes patients with severe knee osteoarthritis who are not candidates for knee replacement surgery.
The main questions it aims to answer are:
- Does genicular nerve radiofrequency reduce knee pain during movement more than hyaluronic acid over 12 months?
- Does it improve knee function and quality of life, and does its effect last longer?
Researchers will compare radiofrequency ablation with hyaluronic acid injection to see which treatment gives greater and longer-lasting pain relief.
Participants will:
- Be randomly assigned to one of the two treatments.
- If assigned to radiofrequency, first receive a diagnostic nerve block with local anesthetic. Only those whose pain decreases by at least 50% will then receive radiofrequency ablation, in a single ultrasound-guided session.
- If assigned to hyaluronic acid, receive a single injection of hyaluronic acid into the knee.
- Attend follow-up visits at 1, 3, 6 and 12 months, where they will rate their pain and answer questionnaires about knee function, overall status and quality of life.
調査の概要
状態
詳細な説明
Knee osteoarthritis is a leading cause of chronic pain and disability. Conventional conservative treatments, such as non-steroidal anti-inflammatory drugs and intra-articular hyaluronic acid, provide partial and time-limited relief. Thermal radiofrequency ablation of the genicular nerves is a minimally invasive technique that interrupts pain transmission from the knee joint. Most published studies have short follow-up (3-6 months), and evidence is scarce in patients with advanced osteoarthritis (Kellgren-Lawrence grade IV) who are not candidates for total knee arthroplasty because of severe comorbidity, morbid obesity or a documented multidisciplinary decision.
Design: single-center, randomized, parallel-group (1:1) controlled trial conducted at Hospital Universitari Joan XXIII de Tarragona (Spain). Patients and clinicians are not blinded; the outcome assessor and the statistician are blinded to treatment allocation.
Randomization: computer-generated sequence (sealedenvelope.com) with variable block sizes, stratified by Kellgren-Lawrence grade (II-III vs IV) and body mass index (<40 vs >=40 kg/m2).
Interventions: in the radiofrequency group, an ultrasound-guided diagnostic block of the superomedial, superolateral and inferomedial genicular nerves (1 ml of 1% lidocaine per nerve) is performed first. Patients with at least 50% pain reduction within 4 hours undergo ultrasound-guided thermal radiofrequency ablation of the same nerves (80 C for 90 seconds per nerve). Patients with a negative block do not receive radiofrequency, are withdrawn from the study and are reported in the CONSORT flow diagram. In the hyaluronic acid group, patients receive a single 6 ml intra-articular injection of high molecular weight hyaluronic acid (hylan G-F 20 or similar).
Sample size: 25 patients per group are required to detect a minimal clinically important difference of 2 points in the visual analogue scale (standard deviation 2.5, power 80%, two-sided alpha 0.05). Allowing for 20% losses over 12 months, 35 patients per group (70 in total) will be included.
A pre-specified subgroup analysis will compare treatment response in Kellgren-Lawrence grade II-III versus grade IV patients, and according to comorbidity (Charlson Comorbidity Index) and body mass index. Health-related quality of life data will be collected for a potential cost-effectiveness analysis.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Laura Pallares Valls, MD
- 電話番号：+34 646973140
- メール：laura-pallares@hotmail.com
研究連絡先のバックアップ
- 名前：Marta Sabater Martos, PhD
- 電話番号：676625869
- メール：Sabaterms@gmail.com
研究場所
-
-
Tarragona
-
Tarragona、Tarragona、スペイン、43005
- Hospital Universitari Joan XXIII de Tarragona
-
コンタクト：
- Laura Pallarès Valls, MD
- 電話番号：+34 646973140
- メール：lpallares.hj23.ics@gencat.cat
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults (18 years or older) with symptomatic knee osteoarthritis of more than 6 months' duration.
- Pain during movement >4 on a 0-10 visual analogue scale.
- Failure of conservative treatment: pain during movement >4 despite at least 3 months of NSAIDs and/or rehabilitation (physical therapy), documented in the medical record. Patients with a documented contraindication to NSAIDs may be included if they have undergone rehabilitation.
- Radiographic Kellgren-Lawrence grade II or III, or
- Kellgren-Lawrence grade IV in patients who are not candidates for total knee arthroplasty because of at least one of the following: body mass index >39.9 kg/m2; Charlson Comorbidity Index >=5 (original, not age-adjusted); or a documented multidisciplinary decision of the Orthopaedic Surgery Department.
- Signed informed consent.
Exclusion Criteria:
- Acute or chronic knee joint infection.
- Intra-articular hyaluronic acid or corticosteroid injection in the previous 6 months.
- Coagulopathy or anticoagulant treatment that does not allow a safe therapeutic window for the procedure.
- Major lower limb surgery in the previous 6 months that may affect function or pain of the index knee (including contralateral total or partial knee arthroplasty, hip arthroplasty, or tibial or femoral osteotomy).
- Cardiac pacemaker or metallic implant (contraindication for radiofrequency).
- Known allergy to hyaluronic acid.
- Severe dementia.
- Institutionalized patients.
- Decompensated systemic disease.
- Active neurological or inflammatory rheumatological disease.
- Terminal oncological disease.
- Inability to understand the study questionnaires.
- Radiofrequency arm only: negative diagnostic genicular nerve block (<50% pain reduction within 4 hours).
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Genicular Nerve Radiofrequency Ablation
Ultrasound-guided diagnostic block of the superomedial, superolateral and inferomedial genicular nerves with 1 ml of 1% lidocaine per nerve. Participants with at least 50% pain reduction within 4 hours undergo ultrasound-guided thermal radiofrequency ablation of the same three nerves (80 C for 90 seconds per nerve) in a single session. Participants with a negative block do not receive radiofrequency and are withdrawn from the study. |
Ultrasound-guided thermal radiofrequency ablation (80 C, 90 seconds per nerve) of the superomedial, superolateral and inferomedial genicular nerves, performed only after a positive diagnostic block (>=50% pain reduction within 4 hours after 1 ml of 1% lidocaine per nerve). |
|
アクティブコンパレータ：Intra-articular Hyaluronic Acid
Single intra-articular injection of 6 ml of high molecular weight hyaluronic acid (hylan G-F 20, Synvisc-One, or similar) into the index knee. |
Single 6 ml intra-articular injection of high molecular weight hyaluronic acid into the index knee. |
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Knee Pain During Movement (Visual Analogue Scale)
時間枠：Baseline, 1, 3, 6 and 12 months after the intervention
|
Pain during movement (walking or climbing stairs) in the index knee, measured on a 100 mm visual analogue scale and recorded in cm with one decimal (0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain. |
Baseline, 1, 3, 6 and 12 months after the intervention
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Knee Pain at Rest (Visual Analogue Scale)
時間枠：Baseline, 1, 3, 6 and 12 months after the intervention
|
Pain at rest in the index knee, measured on a 100 mm visual analogue scale and recorded in cm with one decimal (0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain. |
Baseline, 1, 3, 6 and 12 months after the intervention
|
|
Change in Knee Function (WOMAC)
時間枠：Baseline, 1, 3, 6 and 12 months after the intervention
|
Western Ontario and McMaster Universities Osteoarthritis Index (Likert 3.1). Total score 0-96 and subscales for pain (0-20), stiffness (0-8) and physical function (0-68). Higher scores indicate worse symptoms and function. |
Baseline, 1, 3, 6 and 12 months after the intervention
|
|
Proportion of Participants Achieving the Minimal Clinically Important Difference in Pain
時間枠：1, 3, 6 and 12 months after the intervention
|
Percentage of participants with a reduction of at least 2 points from baseline in pain during movement (visual analogue scale, 0-10). |
1, 3, 6 and 12 months after the intervention
|
|
Analgesic Consumption
時間枠：Baseline, 1, 3, 6 and 12 months after the intervention
|
Number of days with analgesic use in the previous 4 weeks (0-28) and most potent analgesic used (none, paracetamol, NSAID, weak opioid, strong opioid). |
Baseline, 1, 3, 6 and 12 months after the intervention
|
|
Number of Participants With Adverse Events
時間枠：Up to 12 months after the intervention
|
Adverse events related to the diagnostic block, radiofrequency ablation or hyaluronic acid injection, systematically recorded at each visit. |
Up to 12 months after the intervention
|
|
Retreatment or Rescue Treatment
時間枠：Up to 12 months after the intervention
|
Proportion of participants requiring retreatment, rescue treatment (including corticosteroid injection) or indication of total knee arthroplasty, and time to first retreatment or rescue treatment. |
Up to 12 months after the intervention
|
|
Health-Related Quality of Life (EQ-5D-5L)
時間枠：Baseline, 6 and 12 months after the intervention
|
EQ-5D-5L descriptive system (5 dimensions, 5 levels; utility index calculated with the Spanish value set, where 1 = full health and higher values indicate better health) and EQ-VAS (0-100, higher scores indicate better health). |
Baseline, 6 and 12 months after the intervention
|
|
Rate of Negative Diagnostic Genicular Nerve Blocks
時間枠：4 hours after the diagnostic block
|
Percentage of participants allocated to the radiofrequency arm with less than 50% pain reduction within 4 hours after the diagnostic block, who therefore do not receive radiofrequency ablation. |
4 hours after the diagnostic block
|
|
Patient Global Assessment
時間枠：Baseline, 1, 3, 6 and 12 months after the intervention
|
Patient global assessment of the impact of knee osteoarthritis, measured on a 100 mm visual analogue scale (0 = very well, 100 = very poor). Higher scores indicate worse status. |
Baseline, 1, 3, 6 and 12 months after the intervention
|
|
Patient Global Impression of Change (PGIC)
時間枠：1, 3, 6 and 12 months after the intervention
|
Single 7-point item from "very much better" to "very much worse" compared with before the study treatment. Responders are participants reporting "much better" or "very much better". |
1, 3, 6 and 12 months after the intervention
|
|
Proportion of OMERACT-OARSI Responders
時間枠：1, 3, 6 and 12 months after the intervention
|
Responder according to OMERACT-OARSI criteria, based on pain during movement, WOMAC physical function and patient global assessment, each expressed on a 0-100 scale: improvement in pain or function >=50% and >=20 points, or improvement >=20% and >=10 points in at least two of the three domains. |
1, 3, 6 and 12 months after the intervention
|
協力者と研究者
捜査官
- 主任研究者：Laura Pallarès Valls, MD、Hospital Universitari Joan XXIII de Tarragona.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- Ceim-116/2026
- 116/2026 (その他の識別子：CEIm IISPV (Research Ethics Committee) reference number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared publicly, as participant consent for data sharing was not obtained and data are protected under the EU General Data Protection Regulation (GDPR). Data will be pseudonymized using participant codes and entered into REDCap, where the statistical analysis will be performed. Aggregated results will be published in peer-reviewed journals.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。